

Aspartate Aminotransferase acc. to IFCC without pyridoxal phosphate activation

Order information

REF	CONTENT	Analyzer(s) on which cobas c pack(s) can be used
20764949 322	Aspartate Aminotransferase acc. to IFCC (500 tests)	System-ID 07 6494 9 Roche/Hitachi cobas c 311, cobas c 501/502
10759350 190	Calibrator f.a.s. (12 x 3 mL)	Code 401
10759350 360	Calibrator f.a.s. (12 x 3 mL, for USA)	Code 401
12149435 122	Precinorm U plus (10 x 3 mL)	Code 300
12149435 160	Precinorm U plus (10 x 3 mL, for USA)	Code 300
12149443 122	Precipath U plus (10 x 3 mL)	Code 301
12149443 160	Precipath U plus (10 x 3 mL, for USA)	Code 301
10171743 122	Precinorm U (20 x 5 mL)	Code 300
10171778 122	Precipath U (20 x 5 mL)	Code 301
10171760 122	Precipath U (4 x 5 mL)	Code 301
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05947626 160	PreciControl ClinChem Multi 1 (4 x 5 mL, for USA)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
05947774 160	PreciControl ClinChem Multi 2 (4 x 5 mL, for USA)	Code 392
04489357 190	Diluent NaCl 9 % (50 mL)	System-ID 07 6869 3

English

System information

For **cobas c** 311/501 analyzers:

ASTL: ACN 687

SASTL: ACN 587 (STAT, reaction time: 7)

For **cobas c** 502 analyzer:

ASTL: ACN 8687

SASTL: ACN 8587 (STAT, reaction time: 7)

Intended use

In vitro test for the quantitative determination of aspartate aminotransferase (AST) in human serum and plasma on Roche/Hitachi **cobas c** systems.

Summary^{1,2}

The enzyme aspartate aminotransferase (AST) is widely distributed in tissue, principally hepatic, cardiac, muscle, and kidney. Elevated serum levels are found in diseases involving these tissues. Hepatobiliary diseases, such as cirrhosis, metastatic carcinoma, and viral hepatitis also increase serum AST levels. Following myocardial infarction, serum AST is elevated and reaches a peak 2 days after onset.


In patients undergoing renal dialysis or those with vitamin B₆ deficiency, serum AST may be decreased. The apparent reduction in AST may be related to decreased pyridoxal phosphate, the prosthetic group for AST, resulting in an increase in the ratio of apoenzyme to holoenzyme.

2 isoenzymes of AST have been detected, cytoplasmic and mitochondrial. Only the cytoplasmic isoenzyme occurs in normal serum, while the mitochondrial, together with the cytoplasmic isoenzyme, has been detected in the serum of patients with coronary and hepatobiliary disease.

Test principle

This assay follows the recommendations of the IFCC, but was optimized for performance and stability.^{3,4}

AST in the sample catalyzes the transfer of an amino group between L-aspartate and 2-oxoglutarate to form oxaloacetate and L-glutamate. The oxaloacetate then reacts with NADH, in the presence of malate dehydrogenase (MDH), to form NAD⁺.



The rate of the NADH oxidation is directly proportional to the catalytic AST activity. It is determined by measuring the decrease in absorbance.

Reagents - working solutions

R1 TRIS buffer: 264 mmol/L, pH 7.8 (37 °C); L-aspartate: 792 mmol/L; MDH (microorganism): ≥ 24 µkat/L; LDH (microorganisms): ≥ 48 µkat/L; albumin (bovine): 0.25 %; preservative

R2 NADH: ≥ 1.7 mmol/L; 2-oxoglutarate: 94 mmol/L; preservative

R1 is in position A and R2 is in position B and C.

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

For USA: Caution: Federal law restricts this device to sale by or on the order of a physician.

Reagent handling

Ready for use

Storage and stability

ASTL

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

12 weeks

Diluent NaCl 9 %

Shelf life at 2-8 °C:

See expiration date on **cobas c** pack label.

On-board in use and refrigerated on the analyzer:

12 weeks

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable. Serum.

Plasma: Li-heparin and K₂-EDTA plasma

Aspartate Aminotransferase acc. to IFCC without pyridoxal phosphate activation

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability: 24 hours at 15-25 °C⁵
7 days at 2-8 °C⁶

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Application for serum and plasma**cobas c 311 test definition**

Assay type	Rate A		
Reaction time / Assay points	10 / 12-31 (STAT 7 / 12-31)		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Decrease		
Units	U/L (μkat/L)		
Reagent pipetting	Diluent (H ₂ O)		
R1	40 μL	51 μL	
R2	17 μL	20 μL	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	9 μL	–	–
Decreased	9 μL	15 μL	135 μL
Increased	9 μL	–	–

cobas c 501 test definition

Assay type	Rate A		
Reaction time / Assay points	10 / 18-46 (STAT 7 / 18-46)		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Decrease		
Units	U/L (μkat/L)		
Reagent pipetting	Diluent (H ₂ O)		
R1	40 μL	51 μL	
R2	17 μL	20 μL	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	9 μL	–	–
Decreased	9 μL	15 μL	135 μL
Increased	9 μL	–	–

cobas c 502 test definition

Assay type	Rate A		
Reaction time / Assay points	10 / 18-46 (STAT 7 / 18-46)		
Wavelength (sub/main)	700/340 nm		
Reaction direction	Decrease		
Units	U/L (μkat/L)		
Reagent pipetting	Diluent (H ₂ O)		
R1	40 μL	51 μL	
R2	17 μL	20 μL	
Sample volumes	Sample	Sample dilution	
		Sample	Diluent (NaCl)
Normal	9 μL	–	–
Decreased	9 μL	15 μL	135 μL
Increased	18 μL	–	–
Calibration			
Calibrators	S1: H ₂ O		
	S2: C.f.a.s.		
Calibration mode	Linear		
Calibration frequency	2-point calibration		
	• after reagent lot change		
	• as required following quality control procedures		

Calibration interval may be extended based on acceptable verification of calibration by the laboratory.

Traceability: This method has been standardized against the original IFCC formulation using calibrated pipettes together with a manual photometer providing absolute values and the substrate-specific absorptivity, ϵ .⁷

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

Roche/Hitachi **cobas c** systems automatically calculate the analyte activity of each sample.

Conversion factor: U/L x 0.0167 = μkat/L

Limitations - interference

Criterion: Recovery within ± 10 % of initial value at an AST activity of 30 U/L (0.50 μkat/L).

Icterus:⁸ No significant interference up to an I index of 60 for conjugated and unconjugated bilirubin (approximate conjugated and unconjugated bilirubin concentration: 1026 μmol/L or 60 mg/dL).

Hemolysis:⁸ No significant interference up to an H index of 40 (approximate hemoglobin concentration: 25.6 μmol/L or 40 mg/dL).

Contamination with erythrocytes will elevate results, because the analyte level in erythrocytes is higher than in normal sera. The level of interference may be variable depending on the content of analyte in the lysed erythrocytes.

Lipemia (Intralipid):⁸ No significant interference up to an L index of 150. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Aspartate Aminotransferase acc. to IFCC without pyridoxal phosphate activation

Lipemic specimens may cause > Abs flagging. Choose diluted sample treatment for automatic rerun.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{9,10}

Exceptions: Isoniazid can cause artificially low and Furosemide artificially high AST results at therapeutic concentrations.

Cyanokit (Hydroxocobalamin) may cause interference with results.

Physiological plasma concentrations of Sulfasalazine and Sulfapyridine may lead to false results.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.¹¹

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi **cobas c** systems. The latest version of the carry-over evasion list can be found with the NaOHD-SMS-SmpCln1+2-SCCS Method Sheets. For further instructions refer to the operator's manual. **cobas c** 502 analyzer: All special wash programming necessary for avoiding carry-over is available via the **cobas** link, manual input is not required.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges**Measuring range**

5-700 U/L (0.08-11.7 µkat/L)

Determine samples having higher activities via the rerun function. Dilution of samples via the rerun function is a 1:10 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 10.

Lower limits of measurement**Lower detection limit of the test**

5 U/L (0.08 µkat/L)

The lower detection limit represents the lowest measurable analyte level that can be distinguished from 0. It is calculated as the value lying 3 standard deviations above that of the lowest standard (standard 1 + 3 SD, repeatability, n = 21).

Expected values¹²

Acc. to the optimized standard method (comparable to the IFCC method without pyridoxal phosphate activation¹³):

Males: up to 40 U/L (up to 0.67 µkat/L)

Females: up to 32 U/L (up to 0.53 µkat/L)

Calculated values: A factor of 2.13 is used for the conversion from 25 °C to 37 °C.¹⁴

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in an internal protocol with repeatability (n = 21) and intermediate precision (3 aliquots per run, 1 run per day, 20 days).

The following results were obtained:

<i>Repeatability</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>U/L (µkat/L)</i>	<i>U/L (µkat/L)</i>	<i>%</i>
Precinorm U	36.6 (0.611)	0.3 (0.005)	0.8
Precipath U	128 (2.14)	1 (0.02)	0.4
Human serum 1	126 (2.10)	1 (0.02)	0.4
Human serum 2	12.0 (0.200)	0.4 (0.007)	3.1

<i>Intermediate precision</i>	<i>Mean</i>	<i>SD</i>	<i>CV</i>
	<i>U/L (µkat/L)</i>	<i>U/L (µkat/L)</i>	<i>%</i>
Precinorm U	36.7 (0.613)	0.5 (0.008)	1.3
Precipath U	130 (2.17)	1 (0.02)	0.8
Human serum 3	30.0 (0.501)	0.7 (0.012)	2.3
Human serum 4	121 (2.02)	2 (0.03)	1.9

Method comparison

AST values for human serum and plasma samples obtained on a Roche/Hitachi **cobas c** 501 analyzer (y) were compared with those determined using the corresponding reagent on a Roche/Hitachi 917 analyzer (x).

Sample size (n) = 192

Passing/Bablok ¹⁵	Linear regression
$y = 1.000x - 0.149 \text{ U/L}$	$y = 0.991x + 1.22 \text{ U/L}$
$r = 0.970$	$r = 0.999$

The sample activities were between 30.4 and 674 U/L (0.508 and 11.3 µkat/L).

References

- Nagy B. Muscle disease. In: Kaplan LA, Pesce AJ, eds. Clinical Chemistry, theory, analysis, and correlation. St. Louis: Mosby 1984;514.
- Moss DW, Henderson AR, Kachmar JF. Enzymes. In: Tietz NW, ed. Fundamentals of Clinical Chemistry, 3rd ed. Philadelphia, PA: WB Saunders 1987;346-421.
- Bergmeyer HU, Hørdler M, Rej R. Approved recommendation (1985) on IFCC methods for the measurement of catalytic concentration of enzymes. Part 2. IFCC Method for aspartate aminotransferase. J Clin Chem Clin Biochem 1986;24:497-510.
- ECCLS. Determination of the catalytic activity concentration in serum of L-aspartate aminotransferase (EC 2.6.1.1, ASAT). Klin Chem Mitt 1989;20:198-204.
- Tietz NW, ed. Clinical Guide to Laboratory Tests, 3rd ed. Philadelphia PA: WB Saunders Company 1995;76-77.
- Use of Anticoagulants in Diagnostic Laboratory Investigations. WHO Publication WHO/DIL/LAB/99.1 Rev.2.
- Schumann G, Bonora R, Ceriotti F, et al. IFCC Primary Reference Procedures for the Measurement of Catalytic Activity Concentrations of Enzymes at 37 °C – Part 5. Reference Procedure for the Measurement of Catalytic Activity Concentrations of Aspartate Aminotransferase. Clin Chem Lab Med 2002;40(7):725-733.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.
- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Thefeld W, Hoffmeister H, Busch EW, et al. Referenzwerte für die Bestimmungen der Transaminasen GOT und GPT sowie der alkalischen Phosphatase im Serum mit optimierten Standardmethoden. Dtsch Med Wschr 1974;99(8):343-351.
- Klein G, Lehmann P, Michel E, et al. Vergleich der IFCC-Methoden für ALAT, ASAT und GGT bei 37 °C mit den eingeführten Standardmethoden bei 25 °C und 37 °C. Lab Med 1994;18:403-404.
- Zawta B, Klein G, Bablok W. Temperaturumrechnung in der klinischen Enzymologie? Klin Lab 1994;40:23-32.




Aspartate Aminotransferase acc. to IFCC without pyridoxal phosphate activation

- 15 Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard (for USA: see <https://usdiagnostics.roche.com> for definition of symbols used):

	Contents of kit
	Volume after reconstitution or mixing
	Global Trade Item Number

FOR US CUSTOMERS ONLY: LIMITED WARRANTY

Roche Diagnostics warrants that this product will meet the specifications stated in the labeling when used in accordance with such labeling and will be free from defects in material and workmanship until the expiration date printed on the label. THIS LIMITED WARRANTY IS IN LIEU OF ANY OTHER WARRANTY, EXPRESS OR IMPLIED, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE. IN NO EVENT SHALL ROCHE DIAGNOSTICS BE LIABLE FOR INCIDENTAL, INDIRECT, SPECIAL OR CONSEQUENTIAL DAMAGES.

COBAS, COBAS C, PRECINORM, PRECIPATH and PRECICONTROL are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com



Distribution in USA by:
Roche Diagnostics, Indianapolis, IN
US Customer Technical Support 1-800-428-2336